PureTech Health PLC Total Voting Rights (4622H)
August 01 2019 - 2:00AM
UK Regulatory
TIDMPRTC
RNS Number : 4622H
PureTech Health PLC
01 August 2019
PureTech Health plc
Total Voting Rights and Share Capital - Month End Disclosure
Pursuant to DTR 5.6.1 of the Disclosure Guidance and
Transparency Rules:
As at 31 July 2019 the issued share capital of PureTech Health
plc comprised 282,613,821 Ordinary shares of one pence each. There
were no shares held in treasury.
The total number of voting rights in PureTech Health plc is
therefore 282,613,821.
This information may be used by shareholders in their
calculations to determine if they are required to notify their
interest in, or a change to their interest in, PureTech Health plc
under the FCA's Disclosure Guidance and Transparency Rules.
About PureTech Health plc ("PureTech" or the "Company")
PureTech (LSE: PRTC) is an advanced biopharmaceutical company
developing highly differentiated medicines for dysfunctions of the
Brain-Immune-Gut (BIG) axis. The company has gained deep insights
into the connection between these systems and the resulting role in
diseases that have been resistant to established therapeutic
approaches. By harnessing this emerging field of human biology,
PureTech is developing new categories of medicines with the
potential to have great impact on people with serious
disorders.
PureTech is advancing a rich pipeline of innovative therapies
with an unbiased, nimble, and capital efficient R&D model
across its affiliates and its internal R&D pipeline. PureTech's
pipeline comprises two dozen product candidates, including several
clinical-stage programmes, and one product that has been cleared by
the US Food and Drug Administration (FDA). The PureTech pipeline
includes ground-breaking platforms and therapeutic candidates that
were developed in collaboration with some of the world's leading
experts.
PureTech's internal pipeline is centred on lymphatic targeting
and tissue-selective immunomodulation for the potential treatment
of immune and central nervous system disorders, lymphatic
conditions, and cancers. The Company is advancing multiple
platforms to enable oral administration of therapies directly into
the lymphatic system, regulate lymphatic flow and function, and
target immunosuppressive mechanisms in oncology. For more
information, visit www.puretechhealth.com or connect with us on
Twitter @puretechh.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Contact:
PureTech Health FTI Consulting
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRWGUGUMUPBGRG
(END) Dow Jones Newswires
August 01, 2019 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Oct 2023 to Oct 2024